The problem of irreproducible results has gained prominence in recent months. In March, a cancer researcher at Amgen pharmaceutical company reported that its scientists had repeated experiments in 53 'landmark' papers, but managed to confirm findings from only six of the studies. And last year, an internal survey at Bayer HealthCare found that inconsistencies between published findings and the company’s own results caused delays or cancellations in about two-thirds of projects.
Now, 'Reproducibility Initiative', a commercial online portal is offering authors the chance of getting their results validated (albeit for a price). Once the validation studies are complete, the original authors will have the option of publishing the results in the open access journal PLoS ONE, linked to the original publication."